Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cholestatic liver disease · Cystic Fibrosis · PRQR

ProQR Therapeutics N.V

ProQR Therapeutics N.V.

ProQR Therapeutics N.V patent portfolio — 19 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Leiden, NL HQ
2012 Founded
204 Employees
Public company Type
PRQR · NYSE Ticker
Company details
Status
Public
HQ
Leiden, NL
Founded
2012
Employees
204
Programs
6
Drugs
2
Patents
19
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

ProQR Therapeutics N.V patents

19 pharmaceutical patents indexed for ProQR Therapeutics N.V. 0 expire within 24 months.

ProQR Therapeutics N.V has 19 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

19 patents

Patent portfolio

  1. US 12275937

    Stereospecific linkages in RNA editing oligonucleotides

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12203072

    Chemically modified single-stranded rna-editing oligonucleotides

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12180471

    Antisense oligonucleotides for the treatment of Stargardt disease

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12018257

    Single-stranded RNA-editing oligonucleotides

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11920132

    Oligonucleotide therapy for Leber congenital amaurosis

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11851656

    Chemically modified single-stranded RNA-editing oligonucleotides

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11649454

    Single-stranded RNA-editing oligonucleotides

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11479771

    Antisense oligonucleotides for the treatment of eye disease

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11123360

    Oligonucleotides to treat eye disease

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10988763

    Single-stranded RNA-editing oligonucleotides

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10941402

    Chemically modified single-stranded RNA-editing oligonucleotides

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10900041

    Antisense oligonucleotides for use in treating Alzheimer's disease

    Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10889817

    Oligonucleotide therapy for Leber Congenital Amaurosis

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10760076

    Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10617707

    Oligonucleotides to treat eye disease

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10612025

    Antisense oligonucleotides for the treatment of eye disease

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10421963

    Oligonucleotide therapy for leber congenital amaurosis

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9994856

    Method for increasing the activity of a cystic fibrosis transmembrane conductance regulator protein

    Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9605255

    Oligonucleotides for making a change in the sequence of a target RNA molecule present in a living cell

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does ProQR Therapeutics N.V have?

19 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do ProQR Therapeutics N.V patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.